Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 23 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

39%

9 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2
10(43.5%)
Phase 3
6(26.1%)
Phase 1
3(13.0%)
Phase 4
3(13.0%)
N/A
1(4.3%)
23Total
Phase 2(10)
Phase 3(6)
Phase 1(3)
Phase 4(3)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials
NCT07402512Phase 3Recruiting

A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children

Role: lead

NCT06488755Phase 3Recruiting

SIM0718 Treatment of Asthma Clinical Study

Role: lead

NCT06477835Phase 3Completed

A Study to Evaluate the Efficacy and Safety of SIM0718 in Adult and Adolescent Patients With Moderate to Severe Atopic Dermatitis

Role: lead

NCT07393451Phase 2Not Yet Recruiting

A Multicenter Phase 2a Clinical Study to Evaluate SIM0278 in Subjects With Active Lupus Nephritis

Role: lead

NCT06315231Phase 2Recruiting

Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients

Role: lead

NCT06701149Phase 1Not Yet Recruiting

A Comparative Study of the Pharmacokinetics of SIM0718 Injection in Healthy Adult Subjects in China

Role: lead

NCT06176781Phase 3Unknown

The Efficacy and Safety of Edaravone Dexborneol Sequential Therapy in the Treatment of Patients With AIS

Role: lead

NCT05533892Phase 1Unknown

Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC

Role: collaborator

NCT05940883Phase 1Completed

A Study to Evaluate the Pharmacokinetics,Safety and Tolerability of Y-2 Sublingual Tablet in Healthy Adult Subjects

Role: lead

NCT05953103Phase 2Unknown

Evaluate the Efficacy and Safety of Different Doses of Edaravone Dexborneol Concentrated Solution for Injection Combined With Conventional Medical Therapy in the Treatment of Patients With Cerebral Hemorrhage

Role: lead

NCT02748772Phase 3Unknown

Application of Two Anti-angiogenesis Drugs Combined With Chemotherapy in Advanced Colorectal Cancer Under the Background of Precision Medical

Role: collaborator

NCT01430013Phase 2Unknown

Trial of Endostar Combined With CHOPT for T Cell Lymphoma

Role: collaborator

NCT01529164Phase 2Unknown

Efficacy and Safety Study of Recombinant Endostatin Combined With Chemotherapy to Treat Advanced Colorectal Cancer

Role: collaborator

NCT01646853Not ApplicableUnknown

Radiation Dose Study of Concurrent Chemoradiotherapy With Cisplatin Plus Fluorouracil in Oesophageal Cancer

Role: lead

NCT01564329Phase 2Unknown

The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar

Role: lead

NCT01317069Phase 2Unknown

A Randomized, Open, Prospective Clinical Research of Fluorouracil Implant to Improve Surgical Gallbladder Cancer and Bile Duct Cancer

Role: lead

NCT01211002Phase 4Unknown

Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC)

Role: lead

NCT01124253Phase 3Completed

Adjuvant Vinorelbine Plus Cisplatin(NP) Versus NP Plus Endostar in Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer(NSCLC)

Role: collaborator

NCT01055743Phase 2Unknown

The Effect of Fluorouracil Implants Regional Chemotherapy During the Surgical Treatment for Early Stage Hepatocellular Carcinoma

Role: lead

NCT00813332Phase 4Unknown

Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC)

Role: lead